RenovoRx Inc Total Liabilities
RenovoRx Inc total liabilities. Based on the latest financial reports, RenovoRx Inc (RNXT) has total liabilities worth $2.49 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RenovoRx Inc (RNXT) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of RenovoRx Inc (2019–2025)
Total liabilities of RenovoRx Inc from 2019 to 2025. This chart illustrates how RenovoRx Inc's total liabilities have evolved over time, based on quarterly financial data.
RenovoRx Inc Competitors by Total Liabilities
The table below lists competitors of RenovoRx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ActRO Co. Ltd
KQ:290740
|
Korea | ₩55.33 Billion |
|
Crown Confectionery Co Ltd
KO:264900
|
Korea | ₩127.95 Billion |
|
NFON AG
XETRA:NFN
|
Germany | €31.93 Million |
|
Maan Aluminium Limited
NSE:MAANALU
|
India | Rs1.18 Billion |
|
Cassava Sciences Inc
NASDAQ:SAVA
|
USA | $40.23 Million |
|
Taiwan Pelican Express Co Ltd
TW:2642
|
Taiwan | NT$1.76 Billion |
|
Citius Oncology, Inc.
NASDAQ:CTOR
|
USA | $71.71 Million |
|
MS Autotech Co.Ltd
KQ:123040
|
Korea | ₩1.06 Trillion |
Liability Composition Analysis (2019–2025)
This chart breaks down RenovoRx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RNXT current and non-current assets.
Liquidity & Leverage Metrics
RenovoRx Inc Total Liabilities Ratios Explained
RenovoRx Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RenovoRx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RenovoRx Inc (2019–2025)
The table below shows the annual total liabilities of RenovoRx Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.67 Million | -26.57% |
| 2024-12-31 | $3.64 Million | -18.50% |
| 2023-12-31 | $4.47 Million | +305.26% |
| 2022-12-31 | $1.10 Million | +17.48% |
| 2021-12-31 | $938.00K | -94.34% |
| 2020-12-31 | $16.57 Million | +1958.39% |
| 2019-12-31 | $805.00K | -- |
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded i… Read more